OMER
Bearish signalScored 2026-09-27 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Omeros Corporation
- Nom
- Omeros Corporation
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $1.2B
- Employés
- 175
- PDG
- Gregory A. Demopulos
- Site web
- https://www.omeros.com
- Marché
- ANABBHVNCGEMCGENCRVSMGNX
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 30 000 titres (~558 167,00 $ US)
- Insiders
- HANISH ARNOLD CCable Thomas J.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,895,208
Avg sell (VWAP, 90d window) $18.78 vs last close $18.61 (-0.9%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$501,055 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-27
- Liquidity
- Liquid $27,452,767/day · 20d vol
- Last synced
-
2026-10-02 21:10:44
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-23 | Borges David J. | Sell · S · 10b5-1 | 10,000 | $20.95 | $209,500 | Form 4 |
| 2026-08-31 | Cancelmo Peter B | Sell · S | 25,000 | $18.54 | $463,540 | Form 4 |
| 2026-08-28 | Cancelmo Peter B | Sell · S | 25,000 | $18.65 | $466,128 | Form 4 |
| 2026-08-27 | HANISH ARNOLD C | Sell · S | 5,000 | $19.02 | $95,081 | Form 4 |
| 2026-08-26 | HANISH ARNOLD C | Sell · S | 5,000 | $18.53 | $92,632 | Form 4 |
| 2026-08-24 | Borges David J. | Sell · S · 10b5-1 | 906 | $19.10 | $17,305 | Form 4 |
| 2026-08-21 | Borges David J. | Sell · S · 10b5-1 | 10,000 | $18.95 | $189,500 | Form 4 |
| 2026-08-20 | Cable Thomas J. | Sell · S | 15,000 | $18.45 | $276,772 | Form 4 |
| 2026-08-13 | Borges David J. | Sell · S · 10b5-1 | 5,000 | $16.95 | $84,750 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-09-27 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
OMER presents a compelling event-driven catalyst — a significant earnings beat, strong YARTEMLEA launch revenues, and new BlackRock institutional backing — but these positives are severely undermined by catastrophic…
The first sentence of the analysis written for OMER on 2026-09-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Supports a bullish reading. Current ratio 2.76 · operating margin 0.0%
Suggested stop 16.04, nearest stored support minus 0.5 ATR(13.8% under the last close). Reward/risk to the next stored resistance is 0.44. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 2.763 | 1.686 | 4.087 | 3.250 | 4.788 | |
| Quick Ratio | 2.763 | 1.686 | 4.087 | 3.250 | 4.788 | |
| Solvency Ratio | -0.005 | -0.339 | -0.290 | 0.096 | -0.278 | |
| Cash Ratio | 0.124 | 0.043 | 0.133 | 0.081 | 1.947 | |
| Price To Earnings Ratio | -325.996 | -3.659 | -1.739 | 4.913 | -3.592 | |
| Price To Earnings Growth Ratio | 3.325 | -0.084 | 0.003 | -0.039 | 0.140 | |
| Forward Price To Earnings Growth Ratio | 3.325 | -0.084 | 0.003 | -0.039 | 0.140 | |
| Price To Earnings Diluted Ratio | -325.996 | -3.659 | -1.739 | 4.913 | -3.592 | |
| Price To Earnings Diluted Growth Ratio | 3.325 | -0.084 | 0.003 | -0.039 | 0.140 | |
| Price To Book Ratio | -9.000 | -3.147 | -8.212 | 1.655 | 16.858 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -9.393 | -3.858 | 2.761 | -1.637 | -3.644 | |
| Price To Operating Cash Flow Ratio | -9.398 | -3.862 | 2.745 | -1.639 | -3.654 | |
| Debt To Assets Ratio | 0.734 | 0.747 | 0.956 | 0.579 | 0.830 | |
| Debt To Equity Ratio | -1.973 | -1.134 | -14.473 | 3.992 | 14.627 | |
| Debt To Capital Ratio | 2.028 | 8.481 | 1.074 | 0.800 | 0.936 | |
| Long Term Debt To Capital Ratio | 2.389 | -10.395 | 1.082 | 0.721 | 0.929 | |
| Financial Leverage Ratio | -2.686 | -1.517 | -15.141 | 6.897 | 17.631 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -1.487 | -1.871 | 1.402 | -0.634 | -2.119 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.001 | 0.994 | 1.001 | 1.003 | |
| Debt Service Coverage Ratio | -0.225 | -3.437 | -3.632 | -1.353 | -8.668 | |
| Interest Coverage Ratio | 0.000 | -6.859 | -5.334 | -7.197 | -8.827 | |
| Short Term Operating Cash Flow Coverage Ratio | -6.804 | -7.086 | 8.713 | -0.916 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.485 | -0.719 | 0.207 | -0.253 | -0.315 | |
| Capital Expenditure Coverage Ratio | -1,786.062 | -901.836 | 175.413 | -765.336 | -396.108 | |
| Dividend Paid And Capex Coverage Ratio | -1,786.062 | -901.836 | 175.413 | -765.336 | -396.108 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -720.845 | -4.958 | -3.909 | -2.985 | -3.800 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 2.763 | ▲1.076 | ▼-0.552 |
| Quick Ratio | 2.763 | ▲1.076 | ▼-0.552 |
| Solvency Ratio | -0.005 | ▲0.334 | ▲0.158 |
| Cash Ratio | 0.124 | ▲0.081 | ▼-0.342 |
| Price To Earnings Ratio | -325.996 | ▼-322.337 | ▼-259.981 |
| Price To Earnings Growth Ratio | 3.325 | ▲3.409 | ▲2.656 |
| Forward Price To Earnings Growth Ratio | 3.325 | ▲3.409 | ▲2.656 |
| Price To Earnings Diluted Ratio | -325.996 | ▼-322.337 | ▼-259.981 |
| Price To Earnings Diluted Growth Ratio | 3.325 | ▲3.409 | ▲2.656 |
| Price To Book Ratio | -9.000 | ▼-5.853 | ▼-8.631 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -9.393 | ▼-5.535 | ▼-6.239 |
| Price To Operating Cash Flow Ratio | -9.399 | ▼-5.536 | ▼-6.237 |
| Debt To Assets Ratio | 0.734 | ▼-0.013 | ▼-0.035 |
| Debt To Equity Ratio | -1.973 | ▼-0.839 | ▼-2.180 |
| Debt To Capital Ratio | 2.028 | ▼-6.452 | ▼-0.636 |
| Long Term Debt To Capital Ratio | 2.389 | ▲12.783 | ▲3.443 |
| Financial Leverage Ratio | -2.686 | ▼-1.169 | ▼-3.723 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -1.487 | ▲0.384 | ▼-0.545 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | ▼-0.001 | ▲0.001 |
| Debt Service Coverage Ratio | -0.225 | ▲3.212 | ▲3.238 |
| Interest Coverage Ratio | 0.000 | ▲6.859 | ▲5.644 |
| Short Term Operating Cash Flow Coverage Ratio | -6.804 | ▲0.282 | ▼-5.585 |
| Operating Cash Flow Coverage Ratio | -0.485 | ▲0.233 | ▼-0.172 |
| Capital Expenditure Coverage Ratio | -1786.062 | ▼-884.225 | ▼-1051.276 |
| Dividend Paid And Capex Coverage Ratio | -1786.062 | ▼-884.225 | ▼-1051.276 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -720.845 | ▼-715.888 | ▼-573.546 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.09B | $574.7M | $205.2M | $141.8M | $400.9M | |
| Enterprise value | $1.32B | $778.3M | $559.6M | $472.8M | $647.9M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -11.38x | -5.23x | 7.49x | -5.47x | -5.91x | |
| EV / Free cash flow | -11.37x | -5.22x | 7.53x | -5.46x | -5.89x | |
| EV / EBITDA | -720.85x | -4.96x | -3.91x | -2.98x | -3.80x | |
| Net debt / EBITDA | -125.26x | -1.30x | -2.48x | -2.09x | -1.45x | |
| Current ratio | 2.76x | 1.69x | 4.09x | 3.25x | 4.79x | |
| Income quality | 34.66x | 0.95x | -0.63x | 0.47x | 0.57x | |
| Graham number | — | — | — | $5 | — | |
| Graham net-net | -$4 | -$6 | -$4 | -$2 | -$3 | |
| Tax burden | 119.8% | 85.9% | 67.4% | -26.0% | 58.2% | |
| Interest burden | 100.0% | 115.6% | 121.4% | 114.2% | 111.4% | |
| Working capital | $137.6M | $54.6M | $164.6M | $306.9M | $196.2M | |
| Invested capital | $150.1M | $72.2M | $185.2M | $330.1M | $226.2M | |
| Return on assets | -1.0% | -56.6% | -31.1% | 8.0% | -26.6% | |
| Operating ROA | -40.7% | -51.7% | -34.0% | -32.3% | -57.8% | |
| Return on tangible assets | -1.0% | -56.6% | -31.1% | 8.0% | -26.6% | |
| Return on equity | 2.8% | 85.9% | 471.6% | 55.3% | -468.5% | |
| Return on invested capital | -45.3% | -75.4% | -48.6% | -29.5% | -46.6% | |
| Return on capital employed | -49.6% | -85.7% | -50.6% | -35.9% | -47.2% | |
| Earnings yield | -0.3% | -27.3% | -57.4% | 33.4% | -27.8% | |
| Free cash flow yield | -10.6% | -25.9% | 36.2% | -61.1% | -27.4% | |
| Capex / Op. cash flow | -0.1% | -0.1% | 0.6% | -0.1% | -0.3% | |
| Capex / Depreciation | 6.7% | 17.4% | 46.3% | 11.9% | 20.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 3529d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | -3529d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-01 BlackRock Inc. Invests $57.48 Million in Omeros Corporation $OMER BlackRock Inc. purchased a new stake in Omeros Corporation (NASDAQ: OMER) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,044,633 shares of the biopharmaceutical company''s stock, valued at approximately $57,484,000. BlackRock Inc. owned approximately 8.35% of Omeros at the end
- 2026-08-28 What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now? Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-08-25 Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy? Omeros Corporation (OMER) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, OMER''s 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
- 2026-08-15 Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Brokerages Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six analysts that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the
- 2026-08-13 Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript
- 2026-08-12 Omeros Q2 Earnings Call Highlights Omeros NASDAQ: OMER reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, as the company generated positive operating cash flow and reduced its convertible debt after the quarter ended.
- 2026-08-12 Omeros (OMER) Q2 Earnings and Revenues Beat Estimates Omeros (OMER) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to a loss of $0.53 per share a year ago.
- 2026-08-12 Omeros Corporation Reports Second Quarter 2026 Financial Results SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which include: Second Quarter and Recent Highlights YARTEMLEA®, the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-lethal complication of stem cell transplantation, generated gross revenues of $32.2 million in the second quarter of 2026, an incre.
- 2026-08-10 Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026 SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the second quarter of 2026 on Wednesday, August 12, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company''s financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please.
- 2026-08-05 Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) crossed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $11.41 and traded as high as $13.05. Omeros shares last traded at $12.94, with a volume of 1,645,947 shares traded. Analyst Upgrades and